Posttraumatic Stress Disorder as a Catalyst for the Association Between Metabolic Syndrome and Reduced Cortical Thickness.
Posttraumatic Stress Disorder as a Catalyst for the Association Between Metabolic Syndrome and Reduced Cortical Thickness.
复制标题
DOI:
10.1016/j.biopsych.2015.11.023
复制
发表时间:
2016-09-01
影响因子:
10.6
通讯作者:
Miller MW
中科院分区:
文献类型:
--
作者:
Wolf EJ;Sadeh N;Leritz EC;Logue MW;Stoop TB;McGlinchey R;Milberg W;Miller MW
Metabolic syndrome (MetS), defined by a constellation of cardiometabolic pathologies, is highly prevalent among veterans, especially those with posttraumatic stress disorder (PTSD), and poses a major risk for adverse health outcomes, including neurodegeneration and mortality. Given this, we evaluated: (a) the association between MetS and neural integrity, indexed by cortical thickness; (b) the relationship between PTSD and MetS; and (c) if PTSD was associated with cortical thickness indirectly through MetS. The sample consisted of 346 US military veterans (89.3% male; 71.4% white) who deployed to Iraq and/or Afghanistan. Neuroimaging data were available for 274 participants. In whole-brain analyses, MetS was negatively associated with cortical thickness in 2 left and 4 right hemisphere regions: (a) bilateral temporal lobe, including temporal pole, fusiform gyrus, and insula, and extending into occipital cortex (left hemisphere) and orbitofrontal cortex (right hemisphere); (b) bilateral precuneus, posterior cingulate, calcarine, and occipital-parietal cortex; and (c) right rostral anterior cingulate cortex and central sulcus/postcentral gyrus. Path models showed that PTSD predicted MetS (β = .19, p < .001), which, in turn, was associated with reduced cortical thickness (βs from −.29 to – .43, all p <.001). Results from this young veteran sample provide evidence that PTSD confers risk for cardiometabolic pathology and neurodegeneration and raise concern that this cohort may be aging pre-maturely and at risk for substantial medical and cognitive decline. This highlights the need to identify the molecular mechanisms linking PTSD to MetS and for effective interventions to reduce PTSD-related health comorbidities.